
Agentic memory-augmented retrieval and evidence grounding in medicine

Anonymous Author(s)

Affiliation

Address

email

Abstract

1 Large language models (LLMs) hold promise for medical question answering (QA)
2 and clinical decision support, yet remain limited by hallucination, rigid prompting
3 requirements, and restricted context windows. Here, we introduce a unified, open-
4 source LLM-based agentic system that integrates document retrieval, reranking,
5 evidence grounding, and diagnosis generation to support dynamic, multi-step med-
6 ical reasoning. Our system features a lightweight retrieval-augmented generation
7 pipeline coupled with a cache-and-prune memory bank, enabling efficient long-
8 context inference beyond standard LLM limits. The system autonomously invokes
9 specialized tools, eliminating the need for manual prompt engineering or brittle
10 multi-stage templates. Evaluated on five well-known medical QA benchmarks, our
11 system outperforms or closely matches state-of-the-art proprietary (GPT-4) and
12 open-source medical LLMs in multiple-choice and open-ended formats. These re-
13 sults underscore the effectiveness of tool-augmented, evidence-grounded reasoning
14 for building reliable and scalable medical AI systems.

15 **1 Introduction**

16 Large language models (LLMs) are transforming medical research and practice, showing promise in
17 tasks such as medical question answering (QA) and clinical decision support (1; 2; 3; 4). However,
18 some challenges continue to limit their reliability and scalability in real world. One major concern
19 is hallucination, which relates to the generation of confident yet factually incorrect or ungrounded
20 responses. Another issue is the limited context window of current LLMs, which restricts the amount
21 of information they can process at once, often necessitating retrieval-augmented generation (RAG)
22 pipelines. While RAG improves grounding, it typically incorporates a subset of relevant evidence,
23 which can introduce bias or lead to incomplete assessment (5; 6; 7). Additionally, many diagnostic
24 systems require manually engineered multi-stage prompts (8; 9; 10; 11), making them difficult to
25 scale and adapt. To improve reliability, recent work has explored continual pretraining on med-
26 ical corpora (12; 13; 14), instruction fine-tuning and reinforcement learning to enhance medical
27 reasoning (12; 14; 15; 16), and RAG frameworks for grounding model outputs in high-quality ev-
28 idence (5; 6; 8; 9). Despite this progress, most systems focus on either improving reasoning or
29 grounding, rather than jointly optimizing both. Yet, evidence-based medical practice requires sound
30 diagnostic reasoning and alignment with high-quality clinical evidence (17).

31 To address these challenges, we present a unified, agentic system that integrates evidence retrieval,
32 reranking, grounding, and diagnosis generation. Our system uses open-source tools to orchestrate the
33 entire pipeline, from query analysis to final diagnosis, drawing from a comprehensive evidence base
34 that includes PubMed abstracts and full texts, ClinicalTrials.gov entries, the *New England Journal
35 of Medicine* (NEJM) case reports, medical textbooks, and curated Wikipedia content (5; 18; 19;
36 20; 21). To efficiently manage this information, we adopted a two-stage retrieval process including

37 coarse-grained retrieval followed by fine-grained reranking. To circumvent the limitations of LLM
38 context windows, we introduced a cache-and-prune memory mechanism that retains high-relevance
39 documents across reasoning steps, allowing the system to make informed decisions over extended
40 sequences. Our contributions are summarized as follows:

- 41 • We propose a unified, fully-automated system that integrates document retrieval and rerank-
42 ing, evidence grounding, and diagnosis generation through an open-source AI agent.
43 • We present a tool-augmented LLM-based agentic architecture that enables dynamic multi-
44 step tool use, eliminating the need for manually engineered prompts or multi-stage pipelines.
45 • We introduce a cache-and-prune memory bank mechanism that efficiently extends the
46 retention of relevant documents for evidence grounding, enhancing diagnostic accuracy and
47 computational efficiency.

48 2 Related work

49 2.1 Medical reasoning and diagnosis in language models

50 Recent advances in medical reasoning and diagnosis using LLMs have generally progressed along
51 three major directions. The first line of work focused on continual pretraining of publicly available
52 general-purpose LLMs on domain-specific medical corpora, including textbooks, research articles,
53 and podcast transcripts (12; 13; 14; 22). The second direction emphasized instruction tuning or
54 reinforcement learning using medical datasets, which may be manually curated or generated using
55 systems like ChatGPT. These models are fine-tuned through supervised learning or reward feedback to
56 improve chain-of-thought reasoning and emulate realistic doctor-patient interactions (12; 14; 15; 16).
57 Both these strategies aim to enhance medical reasoning skills of general-purpose LLMs. However,
58 despite gains on benchmarks, these models remain vulnerable to hallucinating factually incorrect
59 or unsupported content. A third line of work has explored RAG pipelines to address hallucination
60 risks by grounding model outputs in retrieved medical documents (5; 6; 8; 9; 11). RAG approaches
61 have improved factuality, but often focus on retrieval, without simultaneously optimizing for complex
62 diagnostic reasoning. These observations motivate the need for unified approaches that seamlessly
63 combine robust evidence retrieval with dynamic, multi-step medical reasoning.

64 2.2 Medical AI agents

65 Medical AI agents leverage the reasoning and language capabilities of LLMs to perform complex
66 clinical tasks, including diagnosis and decision support (23). Recent work on medical AI agents
67 has evolved in three directions. The first focuses on role simulation, where agents emulate clinical
68 roles, such as doctors, nurses, and patients, in simulated environments (24; 25; 26; 27; 28). These
69 multi-agent systems aim to model clinical workflows through collaborative interactions and reasoning.
70 The second direction centers on visual question answering, where agents are augmented with domain-
71 specific tools, such as segmentation models for identifying salient regions in medical images and
72 optical character recognition systems for processing textual content from clinical documents (29; 30).
73 While promising, these approaches often lack explicit mechanisms for diagnostic reasoning or robust
74 integration with large-scale medical knowledge bases. The third direction involves tool-augmented
75 LLMs, where agents are equipped with capabilities such as document retrieval, function calling
76 and database access. However, these systems often depend on resource-intensive model retraining
77 or rely on closed-source, paid platforms (*e.g.*, GPT-4) (2; 31; 32; 33; 34), limiting scalability and
78 transparency. Current trends point toward an unmet need for flexible, lightweight and interpretable
79 frameworks that can dynamically orchestrate evidence gathering, reasoning, and clinical decision-
80 making without prohibitive computational overhead. Our work addresses this emerging need by
81 designing a modular, open, and deployment-friendly system for medical diagnosis support.

82 3 Methods

83 Our agentic system comprises three core components (Fig. 1): (1) a lightweight RAG pipeline for
84 efficient evidence retrieval and reranking; (2) an open-source LLM-based agent that autonomously
85 orchestrates diagnostic workflows, from retrieval to reasoning, grounding, and diagnosis generation;




Figure 1: **Overview of the agentic system.** Our pipeline is powered by an open-source LLM-based agent that operates within a fully automated, dynamic workflow. When presented with either multiple-choice or open-ended medical questions, the agent leverages a suite of specialized tools to generate a structured comparison of answer choices or to synthesize plausible options in open-ended scenarios. It then dynamically assesses whether external evidence is needed to answer the question. If no external information is required, the agent proceeds directly to produce a final diagnosis. Otherwise, it initiates a retrieval process, querying a curated knowledge base to obtain the TopK relevant documents and rerank the TopR most informative sources. This evidence pool includes clinical case reports from NEJM, article abstracts from PubMed, full-text articles and textbooks from PubMed Central, clinical trials from ClinicalTrials.gov, and general content from Wikipedia. To manage long-context documents efficiently, the agent employs a cache-and-prune memory bank mechanism. It iteratively reviews B documents in $[R/B]$ batches until sufficient information is gathered, ensuring optimal comprehension within the model’s context window. After synthesizing the selected evidence, the agent integrates key insights to deliver a grounded diagnosis. Its performance is further enhanced by an aid kit of five custom-designed tools, detailed in Section A.4.

86 and (3) a cache-and-prune memory bank that preserves relevant long-context documents to improve
 87 evidence use and diagnostic accuracy. Below we provide additional details on these components.

88 3.1 Lightweight RAG pipeline

89 We implemented a lightweight yet effective RAG pipeline to acquire relevant medical evidence
 90 tailored to patient-specific queries. This pipeline consists of two main stages: document retrieval and
 91 evidence reranking. In the retrieval stage, we utilized SPECTER, a semantic retriever trained with
 92 citation-informed objectives, which improved document-level representation, making it particularly
 93 effective in biomedical and scientific domains (5; 35). Denoted as ϕ , SPECTER retrieves documents
 94 by computing semantic similarity between the query representation x and document embeddings
 95 from the evidence corpus \mathcal{V} , using L2 distance as the similarity metric:

$$TopK(\mathbf{x}, \mathcal{V}) = \arg \max_{\mathbf{v} \in \mathcal{V}} \phi(\mathbf{x}) - \phi(\mathbf{v})_2. \quad (1)$$

96 As summarized in Table S1, our evidence corpus includes diverse resources such as research paper
 97 abstracts and full texts, medical textbooks, clinical case reports, clinical trials, and curated Wikipedia
 98 articles. These are drawn from publicly accessible databases such as PubMed, PubMed Central,
 99 ClinicalTrials.gov, and Wikipedia. To refine the quality of retrieved TopK evidence, we implemented
 100 a reranking stage. Here, a quantized general text embedding model, gte-Qwen2-7B-instruct, was
 101 used to score and rank the candidate snippets at a finer granularity, and denoted as ψ (36; 37). This
 102 ensures that the top-ranked documents are semantically aligned with the query and optimally suited

103 for downstream diagnostic reasoning:

$$\text{TopR}(\mathbf{x}, \mathcal{K}) = \arg \max_{\mathbf{k} \in \mathcal{K}} \cos(\psi(\mathbf{x}), \psi(\mathbf{k})), \quad (2)$$

104 where \mathcal{K} represents the pool of documents retrieved from the six data sources, and \mathcal{R} denotes the
105 final ranked subset selected for use by the AI agent. Together, these two stages ensured that only the
106 most relevant, high-quality evidence is forwarded for diagnostic processing. This design mitigates
107 hallucination risks and supports accurate, grounded medical reasoning.

108 3.2 Agent for diagnostic workflow

109 We integrated an open-source LLM-based agent π as the core multi-step reasoning engine of our
110 system to enable autonomous and interpretable medical decision-making. This agent orchestrates the
111 entire diagnostic workflow, including document retrieval and reranking, patient query interpretation,
112 evidence grounding, and diagnosis generation. We designed the agent to operate using a set of
113 predefined tools (See Section A.4), eliminating the need for manually crafted prompts or rigid,
114 hard-coded stages. Each tool encapsulated a specific function, such as querying external evidence
115 sources, grounding highly-relevant documents, or synthesizing diagnostic conclusions. This allows
116 the agent to perform complex clinical tasks in a structured and interpretable manner. By leveraging
117 explicit tool usage and structured reasoning, the agent interacted dynamically and efficiently with the
118 RAG pipeline and memory bank, enabling long-context, evidence-based clinical inference.

119 Specifically, in the initial step, given a predefined set of tools T , the patient’s background and medical
120 query Q , and instructions I , the AI agent generates a response sequence \mathbf{y} following an autoregressive
121 policy:

$$\pi(\mathbf{y} | T, Q, I) = \prod_t \pi(y_t | T, Q, I, \mathbf{y}_{<t}), \quad (3)$$

122 where $\mathbf{y}_{<t}$ denotes the previously generated tokens up to time step $t - 1$.

123 Furthermore, at each step of the multi-step reasoning process, the agent autonomously selects the most
124 appropriate tool to address the current subtask and produces intermediate responses in a multi-turn
125 conversational format. Let C denote the full conversation history. At each step, the agent selects an
126 action a from the action space A . Formally,

$$a \sim \pi(A | T, Q, I, C). \quad (4)$$

127 During execution, each intermediate reasoning step produced by the agent, along with any cor-
128 responding tool outputs, is appended to the conversation history C , enabling coherent multi-turn
129 interactions. This modular tool-based design empowers the agent to flexibly respond to a wide
130 range of clinical queries while ensuring transparency, reproducibility, and traceability throughout the
131 diagnostic workflow. A detailed description of each tool’s output parameters is provided in Fig. S4.
132 Unlike traditional prompt engineering approaches, the agent autonomously determines when and how
133 to invoke each tool through multi-step reasoning. This enables transparent, step-by-step justification
134 of clinical decisions grounded in retrieved evidence. Importantly, the entire workflow operates locally,
135 preserving patient privacy and minimizing reliance on proprietary APIs or cloud-based infrastructure.

136 3.3 Cache-and-prune memory bank mechanism

137 To overcome the context window limitations of LLMs and ensure persistent access to relevant evidence
138 for the final diagnostic response, we implemented a cache-and-prune memory bank mechanism. This
139 memory module functions as an external, dynamically updated storage that retains high-relevance
140 documents retrieved and reranked during earlier stages of the pipeline. As shown in Algorithm 1, at
141 each reasoning step indexed by i , the AI agent stores the grounded evidence in the memory bank M_i .
142 During the final diagnosis generation, the agent accesses M_i , enabling long-horizon reasoning across
143 multi-turn interactions. To avoid information overload, we designed a cache-and-prune mechanism
144 that filters out outdated or unused evidence, guided by grounding tool usage patterns:

$$M_i = \text{Prune}(M_{i-1} \cup \mathcal{B}_i), \quad i = 1, \dots, \left\lceil \frac{R}{B} \right\rceil, \quad (5)$$

145 where $\mathcal{B}_i = \{\mathbf{r}_i^j \mid j = 1, \dots, B\}$ represents the top-ranked documents from each reranked batch \mathcal{R} ,
146 and $\text{Prune}(\cdot)$ is a logistic filtering function that removes documents that are not grounded by the AI

Algorithm 1 Agentic memory-augmented retrieval and evidence grounding system

```
1: Initialize Document Retriever  $\phi$ , Evidence Reranker  $\psi$ 
2: Initialize AI Agent  $\pi$ , Conversation  $C$ , Memory Bank  $M_1$ 
3: Initialize Evidence database  $\mathcal{V}$ 
4: Given patient background and question  $Q$ , instructions  $I$ , tools  $T$ 
5: AI Agent  $\pi$  generates initial response  $\prod_t \pi(y_t | T, Q, I, \mathbf{y}_{<t})$ 
6: while tool calling do
7:   Retrieve content from the tool calling to update conversation  $C$ 
8:   if tool calling is enable_search then
9:     Retrieve TopK documents  $\arg \text{TopK}_{\mathbf{v} \in \mathcal{V}} - \|\phi(\mathbf{x}) - \phi(\mathbf{v})\|_2$ 
10:    Rerank TopR documents  $\arg \text{TopR}_{\mathbf{k} \in \mathcal{K}} \cos(\psi(\mathbf{x}), \psi(\mathbf{k}))$ 
11:    while  $i \leq \lceil R/B \rceil$  do
12:      Retrieve  $\mathcal{B}_i$  (a batch of  $\mathcal{R}$ ) to update conversation  $C$ 
13:      if tool calling is locate_evidence then
14:        if Relevant document is grounded within <quote></quote> tags then
15:          Update memory bank  $M_i = \text{Prune}(M_{i-1} \cup \mathcal{B}_i)$ 
16:        end if
17:      end if
18:      Remove  $\mathcal{B}_i$  from conversation  $C$ 
19:    end while until Sufficient information is gathered
20:  end if
21: end while
22: if  $M_i$  then
23:   return Final diagnosis  $\prod_t \pi(y_t | T, Q, I, C, M_i, \mathbf{y}_{<t})$ 
24: else
25:   return Final diagnosis  $\prod_t \pi(y_t | T, Q, I, C, \mathbf{y}_{<t})$ 
26: end if
```

147 agent. The final diagnosis is synthesized by conditioning on the complete conversational context,
148 task, instructions, and the curated memory bank M_i :

$$\pi(\mathbf{y} | T, Q, I, C, M_i) = \prod_t \pi(y_t | T, Q, I, C, M_i, \mathbf{y}_{<t}). \quad (6)$$

149 Unlike standard RAG pipelines, which statically inject evidence into the prompt and risk truncation,
150 our memory bank enables selective retention of key information and strategic pruning of less relevant
151 content. This design supports broader context integration and sustained reasoning, mitigating fixed-
152 window constraints and ensuring that only the most salient knowledge informs the agent’s output (5).

153 **3.4 Implementation details**

154 All experiments were conducted locally on a distributed setup with four NVIDIA L40S GPUs,
155 powered by the vLLM inference engine (38). We employed Qwen2.5-72B-Instruct as the primary
156 backbone (i.e., AI agent), with the tensor parallelism and pipeline parallelism settings configured to 4
157 and 1, respectively. By default, the sampling parameters were set to a temperature of 0 and top_p
158 of 1. To address occasional issues with final answer extraction, we re-evaluated the experiments
159 with a temperature of 0.7 and top_p of 0.8. Due to diminished instruction following capabilities
160 after enabling the static YaRN technique, we assigned the maximum context window to 32,768
161 tokens (39). In practice, however, we observed an effective context window limit of approximately
162 10,000 tokens. For each multi-turn conversation, we restricted the maximum number of tokens to
163 8,192. Additionally, we selected the top 3 most relevant evidence documents for the baseline model
164 that operates without tool access. For evidence retrieval, we fixed TopK = 32 per source, resulting
165 in 192 candidate documents from six sources. After reranking, we selected TopR = 32 documents
166 for use by the agent in downstream tasks (5; 6). Lastly, the cache-and-prune memory bank operates
167 with a default batch size $B = 4$ for incremental evidence integration and pruning.

168 **4 Experimental settings**

169 **4.1 Database for evidence retrieval**

170 To ensure grounding in credible and up-to-date medical evidence, we assembled a comprehensive
171 evidence corpus drawn from six trusted sources. They include peer-reviewed articles from PubMed
172 Central, medical textbooks curated from the NLM LitArch Open Access Subset, and registered clinical
173 trials from the National Library of Medicine at the U.S. National Institutes of Health (18; 19; 21). To
174 enhance clinical relevance and provide real-world diagnostic context, we also incorporated clinical
175 case reports published since 2016 in NEJM (20). We also included two supplementary sources, article
176 abstracts and Wikipedia entries, originally curated by Xiong et al. (5). Section A.1 includes a detailed
177 summary and description of each source included in our evidence retrieval database.

178 **4.2 Benchmark evaluation across question formats**

179 To evaluate the performance of our agentic system, we used five widely adopted medical question
180 answering benchmarks: the United States Medical Licensing Examination (USMLE) Step 1, Step
181 2, and Step 3, and the English subsets of MedQA and MedExpQA (6; 40; 41). These datasets
182 encompass a range of medical knowledge, clinical reasoning, and decision-making skills, and are
183 well-established standards for evaluating LLMs. See Section A.2 and Table S3 for more details.

184 We ran experiments in two settings to test our approach: (1) multiple-choice QA, where models
185 choose from given answer options, and (2) open-ended QA, where models generate answers without
186 being given choices. We compared the performance of the agent against proprietary and open-source
187 medical LLMs. Proprietary models included OpenAI GPT-4 and GPT-3.5 (i.e., ChatGPT), while
188 the open-source models evaluated were BioMistral (7B), OpenBioLLM (8B/70B), UltraMedical
189 (8B/70B), and PodGPT (70B) (2; 22; 42; 43; 44). To ensure a fair comparison, we manually ran
190 all open-source models using the VLLM serving engine and applied a consistent zero-shot direct-
191 response prompt. This decision was based on our observation that the performance of some models
192 tended to degrade when presented with more complex instruction prompts. We also set model-specific
193 maximum input lengths and generation token limits to accommodate varying context window sizes.
194 See Section A.3 for more details.

195 For multiple-choice QA experiments, we activated four core tools within the AI agent:
196 `perform_comparison`, `enable_search`, `relevance_analysis`, and `locate_evidence`. Ac-
197 curacy was used as the primary evaluation metric, consistent with standard practices in the
198 field (5; 6; 13; 15; 45). In the open-ended QA setting, we removed predefined answer options
199 from the prompts and extended the `generate_options` tool by building it on top of the same four
200 tools used in the multiple-choice setting. Performance was evaluated by cosine similarity based on
201 two state-of-the-art embedding models: SFR-Embedding-2_R (SFR) from Salesforce Research and
202 gte-Qwen2-7B-instruct (GTE) from Alibaba Group (36; 46). We also employed BERTScore's F1
203 metric, calculated using Microsoft's deberta-xlarge-mnli model, to compare the model-generated
204 answer against ground truth (47). See Section A.4 for more details.

205 **5 Results**

206 **5.1 Evaluation of multiple-choice benchmarks**

207 Our agentic system achieved state-of-the-art performance across multiple-choice medical QA bench-
208 marks, surpassing all evaluated models on USMLE Step 1, Step 2, and MedExpQA (Table 1).
209 Specifically, it achieved 82.98% on Step 1 and 86.24% on Step 2, representing relative improvements
210 of 2.31% and 4.57%, respectively, over GPT-4, which is the strongest baseline. On MedExpQA,
211 where GPT-4 was not available, our model outperformed the next-best model (OpenBioLLM 70B at
212 71.20%) by a relative margin of 7.20%. For USMLE Step 3, our model reached 88.52%, narrowly
213 trailing GPT-4 (89.78%) by only 1.26%. On MedQA, it scored 73.29%, which is 5.58% below GPT-4
214 but still ahead of all open-source models. When compared to the strongest open-source baseline,
215 PodGPT (70B), our model demonstrated consistent and significant gains: 9.58% on Step 1, 13.76%
216 on Step 2, 13.93% on Step 3, 8.25% on MedQA, and 15.20% on MedExpQA.

Table 1: Performance evaluation on multiple choice medical QA benchmarks. Accuracy scores across five benchmarks: USMLE Step 1–3, MedQA, and MedExpQA. The table compares our agentic system with proprietary (GPT-4, ChatGPT) and open-source (BioMistral, OpenBioLLM, UltraMedical, PodGPT) language models. **Bold** and underlined values denote the best and second-best performances for each benchmark, respectively.

Model	USMLE Step 1	USMLE Step 2	USMLE Step 3	MedQA	MedExpQA
GPT-4	<u>80.67</u>	<u>81.67</u>	89.78	78.87	N/A
ChatGPT	<u>51.26</u>	<u>60.83</u>	58.39	50.82	N/A
BioMistral (7B)	34.04	37.61	37.70	41.01	37.60
OpenBioLLM (8B)	47.87	44.04	50.00	47.84	43.20
UltraMedical (8B)	42.55	27.52	34.43	38.49	35.20
OpenBioLLM (70B)	69.15	70.64	68.85	69.13	71.20
UltraMedical (70B)	70.21	55.05	56.56	52.32	50.40
PodGPT (70B)	73.40	72.48	74.59	65.04	63.20
Ours	82.98	86.24	<u>88.52</u>	<u>73.29</u>	78.40

217 5.2 Evaluation of open-ended medical questions

218 Our agentic system achieved the highest performance across all five benchmarks in the open-ended
219 question answering setting, outperforming all baseline models on nearly every metric (Table 2). For
220 semantic textual similarity measured using SFR model, it achieved the top score on four of five
221 benchmarks, including USMLE Step 1 (0.87), Step 2 (0.85), Step 3 (0.86), and MedExpQA (0.84),
222 while ranking second on MedQA (0.85 vs. 0.86 from OpenBioLLM 70B). While measured by the
223 GTE model, it outperformed all baselines on USMLE Steps 1–3 (0.66, 0.62, and 0.65 respectively),
224 and was second-best on MedQA (0.61) and MedExpQA (0.60). Similarly, our system achieved the
225 highest or second-highest BERTScore on all benchmarks, tying for the highest score on USMLE Step
226 1 (0.68), Step 2 (0.67) and MedExpQA (0.65), and ranking second on USMLE Step 3 (0.70 vs. 0.71
from OpenBioLLM 70B) and MedQA (0.67 vs. 0.70 from OpenBioLLM 70B).

Table 2: Performance evaluation on open-ended medical questions. This table reports model performance without answer choices using three embedding-based evaluation metrics: semantic textual similarity scores computed by two state-of-the-art embedding models (SFR and GTE) and BERTScore. Results are shown as mean \pm standard deviation across five benchmarks (USMLE Steps 1–3, MedQA, and MedExpQA). **Bold** indicates the highest score, and underlined indicates the second-highest score for each metric within each benchmark.

Benchmark	Model	BioMistral (7B)	OpenBioLLM (8B)	UltraMedical (8B)	OpenBioLLM (70B)	UltraMedical (70B)	PodGPT (70B)	Ours
USMLE Step 1	SFR	0.79 ± 0.09	0.70 ± 0.12	0.81 ± 0.13	0.85 ± 0.10	0.82 ± 0.11	0.86 ± 0.11	0.87 ± 0.09
	GTE	0.48 ± 0.17	0.38 ± 0.17	0.57 ± 0.21	0.60 ± 0.23	0.63 ± 0.23	<u>0.66 ± 0.24</u>	0.66 ± 0.22
	BERTScore	0.58 ± 0.12	0.51 ± 0.13	0.61 ± 0.16	0.66 ± 0.17	0.64 ± 0.17	0.68 ± 0.20	0.68 ± 0.17
USMLE Step 2	SFR	0.76 ± 0.11	0.71 ± 0.10	0.80 ± 0.11	0.82 ± 0.09	0.80 ± 0.10	0.85 ± 0.10	0.85 ± 0.09
	GTE	0.45 ± 0.19	0.38 ± 0.15	0.52 ± 0.19	0.54 ± 0.19	0.59 ± 0.22	0.62 ± 0.21	0.62 ± 0.22
	BERTScore	0.58 ± 0.11	0.56 ± 0.11	0.61 ± 0.13	0.64 ± 0.13	0.63 ± 0.14	<u>0.66 ± 0.15</u>	0.67 ± 0.15
USMLE Step 3	GTE	0.41 ± 0.18	0.38 ± 0.14	0.53 ± 0.22	<u>0.63 ± 0.26</u>	0.60 ± 0.23	0.63 ± 0.24	0.65 ± 0.22
	BERTScore	0.57 ± 0.11	0.52 ± 0.14	0.60 ± 0.17	0.71 ± 0.19	0.62 ± 0.15	0.67 ± 0.18	0.70 ± 0.17
	SFR	0.76 ± 0.10	0.71 ± 0.12	0.80 ± 0.12	0.86 ± 0.11	0.80 ± 0.11	0.84 ± 0.11	0.85 ± 0.10
MedQA	GTE	0.43 ± 0.18	0.40 ± 0.17	0.53 ± 0.22	0.63 ± 0.26	0.58 ± 0.23	0.60 ± 0.23	0.61 ± 0.23
	BERTScore	0.56 ± 0.12	0.52 ± 0.15	0.60 ± 0.16	0.70 ± 0.19	0.61 ± 0.16	0.65 ± 0.18	0.67 ± 0.18
	SFR	0.76 ± 0.10	0.71 ± 0.11	0.78 ± 0.13	0.81 ± 0.11	0.77 ± 0.13	0.83 ± 0.11	0.84 ± 0.10
MedExpQA	GTE	0.47 ± 0.18	0.40 ± 0.18	0.52 ± 0.22	0.54 ± 0.24	0.55 ± 0.22	<u>0.61 ± 0.23</u>	0.60 ± 0.22
	BERTScore	0.58 ± 0.11	0.53 ± 0.12	0.58 ± 0.15	0.62 ± 0.17	0.60 ± 0.14	<u>0.65 ± 0.17</u>	0.65 ± 0.16

227

228 5.3 Analysis of tool usage

229 Tool usage patterns revealed that the agent adapted its strategy to the complexity of each benchmark
230 (Fig. 2a & Fig. 2b). While `perform_comparison` remained a consistent first-line tool across all
231 exams, `enable_search` was used selectively, indicating the agent’s discretion in deciding when
232 external evidence was necessary to resolve clinical uncertainty. The progressively higher use of

233 `relevance_analysis` and `locate_evidence` tools from Step 1 to Step 3 underscores the agent's
 234 increasing reliance on iterative evidence appraisal and grounding in more advanced clinical scenarios.
 235 This aligns with the expectation that Step 3 questions, which often involve multi-system reasoning
 236 or longitudinal management, demand a deeper chain-of-thought and external validation. The wide
 237 distribution in the number of calls to these tools further supports the hypothesis that the agent's
 238 behavior is not hardcoded but context-dependent. In particular, questions that required repeated
 239 invocations of `relevance_analysis` and `locate_evidence` likely reflected either ambiguous
 240 clinical presentations or sparse initial document matches, prompting further rounds of evidence
 241 screening. Such behavior demonstrates the value of the cache-and-prune memory mechanism,
 242 which allowed the agent to incrementally accumulate, filter, and retain salient information while
 243 pruning irrelevant context. This architecture enabled scalable reasoning over long contexts without
 244 overwhelming the model's input window, supporting robust performance even in highly iterative
 245 diagnostic tasks. Overall, the tool usage patterns validate both the flexibility and compositional
 246 reasoning capabilities of the agent in adapting to a diverse range of clinical question formats.




Figure 2: **Tool usage statistics across USMLE benchmarks.** (a) Bar plot showing the average number of times each tool was invoked per question across the USMLE Step 1, Step 2, and Step 3 benchmarks. Tools include `perform_comparison`, `enable_search`, `relevance_analysis`, and `locate_evidence`. (b) Stacked bar plot indicating the proportion of tool usage frequencies (from 1 to 8 calls) for `relevance_analysis` and `locate_evidence`, grouped by USMLE exam.

Table 3: **Impact of core components of the agentic system.** Performance comparison of the agentic system with ablated versions lacking key components: tool integration, cache-and-prune memory mechanism, and external evidence search. Values for ablations indicate the relative percentage drop in accuracy compared to the full model across USMLE Step 1, Step 2, and Step 3 benchmarks.

Benchmark	USMLE Step 1	USMLE Step 2	USMLE Step 3	Average
Ours	82.98	86.24	88.52	85.91
w/o Tools	-1.07	-3.67	-4.91	-3.22
w/o Cache & Prune	-1.07	-2.75	-3.27	-2.36
w/o Evidence Search	-2.13	-3.67	-6.55	-4.12

247 5.4 Ablation studies

248 We compared performance with and without tool access to evaluate the impact of incorporating
 249 tools into the agentic pipeline. Specifically, we performed evaluation using structured instructions I
 250 without tool access (w/o Tools), and using the same instructions with full access to the toolset T
 251 (Ours). As shown in Table 3, tool integration led to performance improvements: 1.07% on USMLE
 252 Step 1, 3.67% on USMLE Step 2, and 4.91% on Step 3, with an average gain of 3.22% across all of
 253 them. These results underscore the value of equipping the agent with specialized tools.

254 To isolate the contribution of individual components, we conducted targeted ablations. Removing the
 255 `relevance_analysis` and `locate_evidence` tools (denoted w/o Cache & Prune) resulted in an
 256 average drop of 2.36%, with performance reductions of 1.07%, 2.75%, 3.27% on USMLE Step 1-3,

257 highlighting the utility of the iterative memory mechanism. When we removed the `enable_search`
258 tool and the document retrieval and reranking modules (w/o Evidence Search), performance
259 dropped by 4.12% on average, with declines of 2.13%, 3.67%, and 6.55% on Steps 1, 2, and 3,
260 respectively, emphasizing the critical role of external evidence in clinical reasoning.

261 We evaluated how the number of documents retrieved and reranked influenced the performance
262 (Figure 3). Accuracy generally improved with increasing context length up to TopR = 32, beyond
263 which gains plateaued. For Step 2, performance peaked at TopR = 8 with a 7.80% improvement over
264 GPT-4 and remained stable (5.60% gain) from TopR = 32 onward. Step 1 exhibited a similar trend,
265 with gains peaking at 5.50% at TopR = 4 and plateauing beyond TopR = 8. In contrast, while step
266 3 exhibited lower performance relative to GPT-4, its performance fluctuated slightly at lower TopR
267 values and stabilized around -1.40% to -0.50% from TopR = 4 onward. These results highlight
268 the effectiveness of our cache-and-prune memory bank in leveraging extended context efficiently,
269 while also demonstrating the diminishing utility of low-ranked evidence beyond TopR = 32.

270 6 Limitations, broader impact and future work

271 Despite the strong performance of our agen-
272 tic system, some limitations highlight im-
273 portant directions for future research. First,
274 while our system is designed as a general-
275 purpose medical QA agent, its toolset may
276 require domain-specific customization to
277 handle specialized tasks, such as rare dis-
278 ease diagnosis or surgical decision-making.
279 Incorporating adaptive or plug-and-play
280 tools tailored to niche clinical domains
281 could expand its applicability. Second, the
282 sequential execution of tools, particularly
283 for evidence retrieval and analysis, can
284 introduce latency and limit scalability in
285 real-time or high-throughput settings. Fu-
286 ture work will explore parallelized tool ex-
287 ecution, caching strategies across sessions,
288 and learned policies for tool invocation to
289 improve computational efficiency. Third,
290 while our evaluation covered a range of
291 benchmarks, real-world clinical scenarios
292 often involve ambiguous, noisy or incom-
293 plete data. Expanding evaluations to in-
294 clude complex settings such as NEJM clinicopathological conferences, longitudinal case reports, or
295 multimodal inputs will be important to assess robustness in high-stakes use cases (1; 48).

296 Looking ahead, we envision broader societal impacts of our work in democratizing medical expertise
297 through accessible, open-source AI systems. However, these benefits must be pursued alongside
298 safeguards for transparency, accountability, and patient safety. As tool-based agents become more ca-
299 pable, interdisciplinary collaboration between clinicians, ethicists, and technologists will be important
300 to ensure their responsible integration into clinical workflows.

301 7 Conclusion

302 We present a unified, fully automated agentic system that integrates document retrieval, evidence
303 reranking, and grounded diagnosis generation through an open-source agent. By enabling dynamic,
304 multi-step reasoning with seamless tool integration, our system removes the need for manual prompt
305 engineering or complex multi-stage pipelines. To overcome the context window limitations of LLMs,
306 we introduced a cache-and-prune memory bank mechanism that improves evidence synthesis and
307 supports more robust diagnostic reasoning. Across five medical benchmarks, our system consistently
308 delivered strong performance, outperforming or matching leading LLMs. These findings highlight the
309 role of tool-based reasoning in building reliable, scalable, and clinically useful medical AI systems.




Figure 3: **Impact of evidence context length.** The figure shows the relative performance change on USMLE Step 1, Step 2, and Step 3 benchmarks as a function of the number of top reranked documents (TopR) processed by the agentic system. Each point represents the performance difference relative to GPT-4. Different line styles and colors indicate the benchmark type. The y-axis shows the relative difference in accuracy, and the x-axis denotes the number of retrieved documents.

310 **References**

- 311 [1] D. McDuff, M. Schaeckermann, T. Tu, A. Palepu, A. Wang, J. Garrison, K. Singhal, Y. Sharma,
312 S. Azizi, K. Kulkarni, *et al.*, “Towards accurate differential diagnosis with large language
313 models,” *Nature*, pp. 1–7, 2025.
- 314 [2] H. Nori, N. King, S. M. McKinney, D. Carignan, and E. Horvitz, “Capabilities of GPT-4 on
315 medical challenge problems,” *arXiv preprint arXiv:2303.13375*, 2023.
- 316 [3] P. Hager, F. Jungmann, R. Holland, K. Bhagat, I. Hubrecht, M. Knauer, J. Vielhauer,
317 M. Makowski, R. Braren, G. Kaassis, *et al.*, “Evaluation and mitigation of the limitations of large
318 language models in clinical decision-making,” *Nature Medicine*, vol. 30, no. 9, pp. 2613–2622,
319 2024.
- 320 [4] S. Sandmann, S. Hegselmann, M. Fujarski, L. Bickmann, B. Wild, R. Eils, and J. Varghese,
321 “Benchmark evaluation of DeepSeek large language models in clinical decision-making,” *Nature
322 Medicine*, 2025.
- 323 [5] G. Xiong, Q. Jin, Z. Lu, and A. Zhang, “Benchmarking retrieval-augmented generation for
324 medicine,” in *Findings of the Association for Computational Linguistics, ACL 2024, Bangkok,
325 Thailand and virtual meeting, August 11–16, 2024* (L. Ku, A. Martins, and V. Srikanth, eds.),
326 pp. 6233–6251, Association for Computational Linguistics, 2024.
- 327 [6] I. Alonso, M. Oronoz, and R. Agerri, “MedExpQA: Multilingual benchmarking of large
328 language models for medical question answering,” *Artificial Intelligence in Medicine*, vol. 155,
329 p. 102938, 2024.
- 330 [7] R. Yang, Y. Ning, E. Keppo, M. Liu, C. Hong, D. S. Bitterman, J. C. L. Ong, D. S. W. Ting,
331 and N. Liu, “Retrieval-augmented generation for generative artificial intelligence in health care,”
332 *npj Health Systems*, vol. 2, no. 1, p. 2, 2025.
- 333 [8] M. Jeong, J. Sohn, M. Sung, and J. Kang, “Improving medical reasoning through retrieval
334 and self-reflection with retrieval-augmented large language models,” *Bioinformatics*, vol. 40,
335 no. Supplement_1, pp. i119–i129, 2024.
- 336 [9] G. Xiong, Q. Jin, X. Wang, M. Zhang, Z. Lu, and A. Zhang, “Improving retrieval-augmented
337 generation in medicine with iterative follow-up questions,” in *Biocomputing 2025: Proceedings
338 of the Pacific Symposium*, pp. 199–214, World Scientific, 2024.
- 339 [10] R. Alzghoul, A. Ayaabdelhaq, A. Tabaza, and A. Altamimi, “CLD-MEC at MEDIQA-CORR
340 2024 task: GPT-4 multi-stage clinical chain of thought prompting for medical errors detection
341 and correction,” in *Proceedings of the 6th Clinical Natural Language Processing Workshop,
342 ClinicalNLP@NAACL 2024, Mexico City, Mexico, June 21, 2024* (T. Naumann, A. B. Abacha,
343 S. Bethard, K. Roberts, and D. S. Bitterman, eds.), pp. 537–556, Association for Computational
344 Linguistics, 2024.
- 345 [11] Y. Chen, P. Sun, X. Li, and X. Chu, “MRD-RAG: Enhancing medical diagnosis with multi-round
346 retrieval-augmented generation,” *arXiv preprint arXiv:2504.07724*, 2025.
- 347 [12] C. Wu, W. Lin, X. Zhang, Y. Zhang, W. Xie, and Y. Wang, “PMC-LLaMA: Toward building
348 open-source language models for medicine,” *Journal of the American Medical Informatics
349 Association*, vol. 31, no. 9, pp. 1833–1843, 2024.
- 350 [13] X. Wang, N. Chen, J. Chen, Y. Hu, Y. Wang, X. Wu, A. Gao, X. Wan, H. Li, and B. Wang,
351 “Apollo: An lightweight multilingual medical LLM towards democratizing medical AI to 6B
352 people,” *arXiv preprint arXiv:2403.03640*, 2024.
- 353 [14] P. Qiu, C. Wu, X. Zhang, W. Lin, H. Wang, Y. Zhang, Y. Wang, and W. Xie, “Towards building
354 multilingual language model for medicine,” *Nature Communications*, vol. 15, no. 1, p. 8384,
355 2024.

- 356 [15] H. Zhang, J. Chen, F. Jiang, F. Yu, Z. Chen, G. Chen, J. Li, X. Wu, Z. Zhang, Q. Xiao, X. Wan,
357 B. Wang, and H. Li, “HuatuoGPT, towards taming language model to be a doctor,” in *Findings
358 of the Association for Computational Linguistics: EMNLP 2023, Singapore, December 6-10,
359 2023* (H. Bouamor, J. Pino, and K. Bali, eds.), pp. 10859–10885, Association for Computational
360 Linguistics, 2023.
- 361 [16] J. Chen, Z. Cai, K. Ji, X. Wang, W. Liu, R. Wang, J. Hou, and B. Wang, “HuatuoGPT-o1,
362 Towards medical complex reasoning with LLMs,” *arXiv preprint arXiv:2412.18925*, 2024.
- 363 [17] V. Subbiah, “The next generation of evidence-based medicine,” *Nature Medicine*, vol. 29, no. 1,
364 pp. 49–58, 2023.
- 365 [18] National Library of Medicine (US), “Pubmed Central,” 2024. National Center for Biotechnology
366 Information, U.S. National Library of Medicine.
- 367 [19] J. E. Gillen, T. Tse, N. C. Ide, and A. T. McCray, “Design, implementation and management of
368 a web-based data entry system for ClinicalTrials.gov,” in *MEDINFO 2004 - Proceedings of the
369 11th World Congress on Medical Informatics, San Francisco, California, USA, September 7-11,
370 2004* (M. Fieschi, E. W. Coiera, and Y. J. Li, eds.), vol. 107 of *Studies in Health Technology
371 and Informatics*, pp. 1466–1470, IOS Press, 2004.
- 372 [20] E. W. Campion, L. Scott, A. Graham, J. M. Prince, S. Morrissey, and J. M. Drazen, “NEJM.org
373 — 20 years on the web,” *New England Journal of Medicine*, vol. 375, no. 10, pp. 993–994, 2016.
- 374 [21] National Center for Biotechnology Information (US), “About Bookshelf [Internet].” <https://www.ncbi.nlm.nih.gov/books/about/openaccess/>, 2010. NLM LitArch Open Access
375 Subset.
- 377 [22] S. Jia, S. Bit, E. Searls, M. V. Lauber, L. A. Claus, P. Fan, V. H. Jasodanand, D. Veerapaneni,
378 W. M. Wang, R. Au, et al., “PodGPT: An audio-augmented large language model for research
379 and education,” *npj Biomedical Innovations*, 2025.
- 380 [23] J. Luo, W. Zhang, Y. Yuan, Y. Zhao, J. Yang, Y. Gu, B. Wu, B. Chen, Z. Qiao, Q. Long,
381 R. Tu, X. Luo, W. Ju, Z. Xiao, Y. Wang, M. Xiao, C. Liu, J. Yuan, S. Zhang, Y. Jin, F. Zhang,
382 X. Wu, H. Zhao, D. Tao, P. S. Yu, and M. Zhang, “Large language model agent: A survey on
383 methodology, applications and challenges,” *arXiv preprint arXiv:2503.21460*, 2025.
- 384 [24] H. Yu, J. Zhou, L. Li, S. Chen, J. Gallifant, A. Shi, X. Li, W. Hua, M. Jin, G. Chen, Y. Zhou,
385 Z. Li, T. Gupte, M. Chen, Z. Azizi, Y. Zhang, T. L. Assimes, X. Ma, D. S. Bitterman, L. Lu,
386 and L. Fan, “AIPatient: Simulating patients with EHRs and LLM powered agentic workflow,”
387 *arXiv preprint arXiv:2409.18924*, 2024.
- 388 [25] J. Li, S. Wang, M. Zhang, W. Li, Y. Lai, X. Kang, W. Ma, and Y. Liu, “Agent Hospital: A
389 simulacrum of hospital with evolvable medical agents,” *arXiv preprint arXiv:2405.02957*, 2024.
- 390 [26] W. Yan, H. Liu, T. Wu, Q. Chen, W. Wang, H. Chai, J. Wang, W. Zhao, Y. Zhang, R. Zhang,
391 and L. Zhu, “ClinicalLab: Aligning agents for multi-departmental clinical diagnostics in the
392 real world,” *arXiv preprint arXiv:2406.13890*, 2024.
- 393 [27] M. K. Almansoori, K. Kumar, and H. Cholakkal, “Self-evolving multi-agent simulations for
394 realistic clinical interactions,” *arXiv preprint arXiv:2503.22678*, 2025.
- 395 [28] H. Li, W. Pan, S. Rajendran, C. Zang, and F. Wang, “TrialGenie: Empowering clinical trial
396 design with agentic intelligence and real world data,” *medRxiv*, 2025.
- 397 [29] A. Fallahpour, J. Ma, A. Munim, H. Lyu, and B. Wang, “MedRAX: Medical reasoning agent
398 for chest X-ray,” *arXiv preprint arXiv:2502.02673*, 2025.
- 399 [30] N. Sharma, “CXR-Agent: Vision-language models for chest X-ray interpretation with uncer-
400 tainty aware radiology reporting,” *arXiv preprint arXiv:2407.08811*, 2024.
- 401 [31] S. Gao, R. Zhu, Z. Kong, A. Noori, X. Su, C. Ginder, T. Tsiligkaridis, and M. Zitnik, “Tx-
402 Agent: An AI agent for therapeutic reasoning across a universe of tools,” *arXiv preprint
403 arXiv:2503.10970*, 2025.

- 404 [32] P. Lu, B. Chen, S. Liu, R. Thapa, J. Boen, and J. Zou, “OctoTools: An agentic framework with
405 extensible tools for complex reasoning,” *arXiv preprint arXiv:2502.11271*, 2025.
- 406 [33] Y. Liao, S. Jiang, Y. Wang, and Y. Wang, “ReflecTool: Towards reflection-aware tool-augmented
407 clinical agents,” *arXiv preprint arXiv:2410.17657*, 2024.
- 408 [34] A. J. Goodell, S. N. Chu, D. Rouholiman, and L. F. Chu, “Large language model agents can use
409 tools to perform clinical calculations,” *npj Digital Medicine*, vol. 8, no. 1, 2025.
- 410 [35] A. Cohan, S. Feldman, I. Beltagy, D. Downey, and D. S. Weld, “SPECTER: Document-level
411 representation learning using citation-informed Transformers,” in *Proceedings of the 58th*
412 *Annual Meeting of the Association for Computational Linguistics, ACL 2020, Online, July 5-10,*
413 *2020* (D. Jurafsky, J. Chai, N. Schluter, and J. R. Tetreault, eds.), pp. 2270–2282, Association
414 for Computational Linguistics, 2020.
- 415 [36] Z. Li, X. Zhang, Y. Zhang, D. Long, P. Xie, and M. Zhang, “Towards general text embeddings
416 with multi-stage contrastive learning,” *arXiv preprint arXiv:2308.03281*, 2023.
- 417 [37] Bitsandbytes Development Team, “Accessible large language models via k-bit quantization for
418 PyTorch,” 2024. GitHub repository.
- 419 [38] W. Kwon, Z. Li, S. Zhuang, Y. Sheng, L. Zheng, C. H. Yu, J. Gonzalez, H. Zhang, and I. Stoica,
420 “Efficient memory management for large language model serving with PagedAttention,” in
421 *Proceedings of the 29th Symposium on Operating Systems Principles, SOSP 2023, Koblenz,*
422 *Germany, October 23-26, 2023* (J. Flinn, M. I. Seltzer, P. Druschel, A. Kaufmann, and J. Mace,
423 eds.), pp. 611–626, Association for Computing Machinery, 2023.
- 424 [39] B. Peng, J. Quesnelle, H. Fan, and E. Shippole, “YaRN: Efficient context window extension
425 of large language models,” in *The Twelfth International Conference on Learning Represen-*
426 *tations, ICLR 2024, Vienna, Austria, May 7-11, 2024*, International Conference on Learning
427 Representations, 2024.
- 428 [40] T. H. Kung, M. Cheatham, A. Medenilla, C. Sillos, L. De Leon, C. Elepaño, M. Madriaga,
429 R. Aggabao, G. Diaz-Candido, J. Maningo, *et al.*, “Performance of ChatGPT on USMLE:
430 Potential for AI-assisted medical education using large language models,” *PLOS Digital Health*,
431 vol. 2, no. 2, p. e0000198, 2023.
- 432 [41] D. Jin, E. Pan, N. Oufattole, W.-H. Weng, H. Fang, and P. Szolovits, “What disease does this
433 patient have? A large-scale open domain question answering dataset from medical exams,”
434 *Applied Sciences*, vol. 11, no. 14, 2021.
- 435 [42] Y. Labrak, A. Bazoge, E. Morin, P. Gourraud, M. Rouvier, and R. Dufour, “BioMistral: A
436 collection of open-source pretrained large language models for medical domains,” in *Findings*
437 *of the Association for Computational Linguistics, ACL 2024, Bangkok, Thailand and virtual*
438 *meeting, August 11-16, 2024* (L. Ku, A. Martins, and V. Srikumar, eds.), pp. 5848–5864,
439 Association for Computational Linguistics, 2024.
- 440 [43] Meta AI, “How Llama is helping Saama deliver new possibilities in per-
441 sonalized medicine and data-driven care.” [https://ai.meta.com/blog/](https://ai.meta.com/blog/saama-data-driven-care-built-with-llama)
442 saama-data-driven-care-built-with-llama, 2025.
- 443 [44] K. Zhang, S. Zeng, E. Hua, N. Ding, Z. Chen, Z. Ma, H. Li, G. Cui, B. Qi, X. Zhu, X. Lv,
444 J. Hu, Z. Liu, and B. Zhou, “UltraMedical: Building specialized generalists in biomedicine,”
445 in *Advances in Neural Information Processing Systems 38: Annual Conference on Neural*
446 *Information Processing Systems 2024, NeurIPS 2024, Vancouver, BC, Canada, December 10*
447 *- 15, 2024* (A. Globersons, L. Mackey, D. Belgrave, A. Fan, U. Paquet, J. M. Tomczak, and
448 C. Zhang, eds.), 2024.
- 449 [45] Y. Gao, D. Dligach, T. A. Miller, J. R. Caskey, B. Sharma, M. M. Churpek, and M. Afshar,
450 “DR.BENCH: Diagnostic reasoning benchmark for clinical natural language processing,” *Jour-*
451 *nal of Biomedical Informatics*, vol. 138, p. 104286, 2023.
- 452 [46] R. Meng, Y. Liu, S. R. Joty, C. Xiong, Y. Zhou, and S. Yavuz, “SFR-Embedding-2: Advanced
453 text embedding with multi-stage training,” 2024.

- 454 [47] T. Zhang, V. Kishore, F. Wu, K. Q. Weinberger, and Y. Artzi, “BERTScore: Evaluating text
455 generation with BERT,” in *The Eleventh International Conference on Learning Representations,
456 ICLR 2020, Addis Ababa, Ethiopia, April 26-30, 2020*, International Conference on Learning
457 Representations, 2020.
- 458 [48] A. V. Eriksen, S. Möller, and J. Ryg, “Use of GPT-4 to diagnose complex clinical cases,” *NEJM
459 AI*, vol. 1, no. 1, p. A1p2300031, 2024.
- 460 [49] A. Yang, B. Yang, B. Zhang, B. Hui, B. Zheng, B. Yu, C. Li, D. Liu, F. Huang, H. Wei, H. Lin,
461 J. Yang, J. Tu, J. Zhang, J. Yang, J. Yang, J. Zhou, J. Lin, K. Dang, K. Lu, K. Bao, K. Yang,
462 L. Yu, M. Li, M. Xue, P. Zhang, Q. Zhu, R. Men, R. Lin, T. Li, T. Xia, X. Ren, X. Ren, Y. Fan,
463 Y. Su, Y. Zhang, Y. Wan, Y. Liu, Z. Cui, Z. Zhang, and Z. Qiu, “Qwen2.5 technical report,”
464 *arXiv preprint arXiv:2412.15115*, 2024.
- 465 [50] R. Rafailov, A. Sharma, E. Mitchell, C. D. Manning, S. Ermon, and C. Finn, “Direct prefer-
466 ence optimization: Your language model is secretly a reward model,” in *Advances in Neural
467 Information Processing Systems* (A. Oh, T. Naumann, A. Globerson, K. Saenko, M. Hardt, and
468 S. Levine, eds.), vol. 36, pp. 53728–53741, Curran Associates, Inc., 2023.
- 469 [51] E. J. Hu, Y. Shen, P. Wallis, Z. Allen-Zhu, Y. Li, S. Wang, L. Wang, and W. Chen, “LoRA: Low-
470 rank adaptation of large language models,” in *The Tenth International Conference on Learning
471 Representations, ICLR 2022, Virtual Event, April 25-29, 2022*, International Conference on
472 Learning Representations, 2022.

473 **NeurIPS Paper Checklist**

474 **1. Claims**

475 Question: Do the main claims made in the abstract and introduction accurately reflect the
476 paper's contributions and scope?

477 Answer: [Yes]

478 Justification: The main contributions and scope are carefully articulated in both the ab-
479 stract and the introduction. To ensure clarity, we also provide a concise summary of the
480 contributions at the end of the introduction (see Section 1).

481 Guidelines:

- 482 • The answer NA means that the abstract and introduction do not include the claims
483 made in the paper.
- 484 • The abstract and/or introduction should clearly state the claims made, including the
485 contributions made in the paper and important assumptions and limitations. A No or
486 NA answer to this question will not be perceived well by the reviewers.
- 487 • The claims made should match theoretical and experimental results, and reflect how
488 much the results can be expected to generalize to other settings.
- 489 • It is fine to include aspirational goals as motivation as long as it is clear that these goals
490 are not attained by the paper.

491 **2. Limitations**

492 Question: Does the paper discuss the limitations of the work performed by the authors?

493 Answer: [Yes]

494 Justification: Yes, we explicitly discuss three key limitations of our current work in Section 6,
495 along with proposed directions to address them in future research.

496 Guidelines:

- 497 • The answer NA means that the paper has no limitation while the answer No means that
498 the paper has limitations, but those are not discussed in the paper.
- 499 • The authors are encouraged to create a separate "Limitations" section in their paper.
- 500 • The paper should point out any strong assumptions and how robust the results are to
501 violations of these assumptions (e.g., independence assumptions, noiseless settings,
502 model well-specification, asymptotic approximations only holding locally). The authors
503 should reflect on how these assumptions might be violated in practice and what the
504 implications would be.
- 505 • The authors should reflect on the scope of the claims made, e.g., if the approach was
506 only tested on a few datasets or with a few runs. In general, empirical results often
507 depend on implicit assumptions, which should be articulated.
- 508 • The authors should reflect on the factors that influence the performance of the approach.
509 For example, a facial recognition algorithm may perform poorly when image resolution
510 is low or images are taken in low lighting. Or a speech-to-text system might not be
511 used reliably to provide closed captions for online lectures because it fails to handle
512 technical jargon.
- 513 • The authors should discuss the computational efficiency of the proposed algorithms
514 and how they scale with dataset size.
- 515 • If applicable, the authors should discuss possible limitations of their approach to
516 address problems of privacy and fairness.
- 517 • While the authors might fear that complete honesty about limitations might be used by
518 reviewers as grounds for rejection, a worse outcome might be that reviewers discover
519 limitations that aren't acknowledged in the paper. The authors should use their best
520 judgment and recognize that individual actions in favor of transparency play an impor-
521 tant role in developing norms that preserve the integrity of the community. Reviewers
522 will be specifically instructed to not penalize honesty concerning limitations.

523 **3. Theory assumptions and proofs**

524 Question: For each theoretical result, does the paper provide the full set of assumptions and
525 a complete (and correct) proof?

526 Answer: [NA]

527 Justification: This paper does not present any theoretical results; therefore, no assumptions
528 or formal proofs are provided.

529 Guidelines:

- 530 • The answer NA means that the paper does not include theoretical results.
- 531 • All the theorems, formulas, and proofs in the paper should be numbered and cross-
532 referenced.
- 533 • All assumptions should be clearly stated or referenced in the statement of any theorems.
- 534 • The proofs can either appear in the main paper or the supplemental material, but if
535 they appear in the supplemental material, the authors are encouraged to provide a short
536 proof sketch to provide intuition.
- 537 • Inversely, any informal proof provided in the core of the paper should be complemented
538 by formal proofs provided in appendix or supplemental material.
- 539 • Theorems and Lemmas that the proof relies upon should be properly referenced.

540 4. Experimental result reproducibility

541 Question: Does the paper fully disclose all the information needed to reproduce the main ex-
542 perimental results of the paper to the extent that it affects the main claims and/or conclusions
543 of the paper (regardless of whether the code and data are provided or not)?

544 Answer: [Yes]

545 Justification: We provide a comprehensive description of our methods in Section 3 and in-
546 clude full implementation and experimental details in Section 4, ensuring that all information
547 necessary to reproduce the results and support the paper’s conclusions is fully disclosed.

548 Guidelines:

- 549 • The answer NA means that the paper does not include experiments.
- 550 • If the paper includes experiments, a No answer to this question will not be perceived
551 well by the reviewers: Making the paper reproducible is important, regardless of
552 whether the code and data are provided or not.
- 553 • If the contribution is a dataset and/or model, the authors should describe the steps taken
554 to make their results reproducible or verifiable.
- 555 • Depending on the contribution, reproducibility can be accomplished in various ways.
556 For example, if the contribution is a novel architecture, describing the architecture fully
557 might suffice, or if the contribution is a specific model and empirical evaluation, it may
558 be necessary to either make it possible for others to replicate the model with the same
559 dataset, or provide access to the model. In general, releasing code and data is often
560 one good way to accomplish this, but reproducibility can also be provided via detailed
561 instructions for how to replicate the results, access to a hosted model (e.g., in the case
562 of a large language model), releasing of a model checkpoint, or other means that are
563 appropriate to the research performed.
- 564 • While NeurIPS does not require releasing code, the conference does require all submis-
565 sions to provide some reasonable avenue for reproducibility, which may depend on the
566 nature of the contribution. For example
 - 567 (a) If the contribution is primarily a new algorithm, the paper should make it clear how
568 to reproduce that algorithm.
 - 569 (b) If the contribution is primarily a new model architecture, the paper should describe
570 the architecture clearly and fully.
 - 571 (c) If the contribution is a new model (e.g., a large language model), then there should
572 either be a way to access this model for reproducing the results or a way to reproduce
573 the model (e.g., with an open-source dataset or instructions for how to construct
574 the dataset).
 - 575 (d) We recognize that reproducibility may be tricky in some cases, in which case
576 authors are welcome to describe the particular way they provide for reproducibility.
577 In the case of closed-source models, it may be that access to the model is limited in
578 some way (e.g., to registered users), but it should be possible for other researchers
579 to have some path to reproducing or verifying the results.

580 **5. Open access to data and code**

581 Question: Does the paper provide open access to the data and code, with sufficient instruc-
582 tions to faithfully reproduce the main experimental results, as described in supplemental
583 material?

584 Answer: [Yes]

585 Justification: As detailed in Section A.7, we clearly outline the accessibility of all re-
586 sources used in our study. The source code will be released publicly via GitHub with
587 accompanying documentation. While the clinical case data from the *New England Journal*
588 of Medicine (NEJM) are subject to licensing restrictions and cannot be publicly shared,
589 all other datasets will be made available via Hugging Face under the Creative Commons
590 Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license, reflecting the most
591 restrictive terms of the PubMed Central articles included in our corpus.

592 Guidelines:

- 593 • The answer NA means that paper does not include experiments requiring code.
- 594 • Please see the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- 595 • While we encourage the release of code and data, we understand that this might not be
596 possible, so “No” is an acceptable answer. Papers cannot be rejected simply for not
597 including code, unless this is central to the contribution (e.g., for a new open-source
598 benchmark).
- 599 • The instructions should contain the exact command and environment needed to run to
600 reproduce the results. See the NeurIPS code and data submission guidelines (<https://nips.cc/public/guides/CodeSubmissionPolicy>) for more details.
- 601 • The authors should provide instructions on data access and preparation, including how
602 to access the raw data, preprocessed data, intermediate data, and generated data, etc.
- 603 • The authors should provide scripts to reproduce all experimental results for the new
604 proposed method and baselines. If only a subset of experiments are reproducible, they
605 should state which ones are omitted from the script and why.
- 606 • At submission time, to preserve anonymity, the authors should release anonymized
607 versions (if applicable).
- 608 • Providing as much information as possible in supplemental material (appended to the
609 paper) is recommended, but including URLs to data and code is permitted.

612 **6. Experimental setting/details**

613 Question: Does the paper specify all the training and test details (e.g., data splits, hyper-
614 parameters, how they were chosen, type of optimizer, etc.) necessary to understand the
615 results?

616 Answer: [Yes]

617 Justification: We provide a comprehensive description of the implementation setup and
618 experimental settings in Section 3.4 and Section 4, including model configurations, hyper-
619 parameter choices, database for evidence retrieval, benchmark evaluation across question
620 formats, ensuring clarity and reproducibility of the reported results.

621 Guidelines:

- 622 • The answer NA means that the paper does not include experiments.
- 623 • The experimental setting should be presented in the core of the paper to a level of detail
624 that is necessary to appreciate the results and make sense of them.
- 625 • The full details can be provided either with the code, in appendix, or as supplemental
626 material.

627 **7. Experiment statistical significance**

628 Question: Does the paper report error bars suitably and correctly defined or other appropriate
629 information about the statistical significance of the experiments?

630 Answer: [No]

631 Justification: Due to the substantial computational cost associated with large-scale LLM
632 evaluations, all reported results in our experiments are based on a single run. As a result, we
633 do not include error bars or statistical significance measures.

634 Guidelines:

- 635 • The answer NA means that the paper does not include experiments.
- 636 • The authors should answer "Yes" if the results are accompanied by error bars, confi-
637 dence intervals, or statistical significance tests, at least for the experiments that support
638 the main claims of the paper.
- 639 • The factors of variability that the error bars are capturing should be clearly stated (for
640 example, train/test split, initialization, random drawing of some parameter, or overall
641 run with given experimental conditions).
- 642 • The method for calculating the error bars should be explained (closed form formula,
643 call to a library function, bootstrap, etc.)
- 644 • The assumptions made should be given (e.g., Normally distributed errors).
- 645 • It should be clear whether the error bar is the standard deviation or the standard error
646 of the mean.
- 647 • It is OK to report 1-sigma error bars, but one should state it. The authors should
648 preferably report a 2-sigma error bar than state that they have a 96% CI, if the hypothesis
649 of Normality of errors is not verified.
- 650 • For asymmetric distributions, the authors should be careful not to show in tables or
651 figures symmetric error bars that would yield results that are out of range (e.g. negative
652 error rates).
- 653 • If error bars are reported in tables or plots, The authors should explain in the text how
654 they were calculated and reference the corresponding figures or tables in the text.

655 8. Experiments compute resources

656 Question: For each experiment, does the paper provide sufficient information on the com-
657 puter resources (type of compute workers, memory, time of execution) needed to reproduce
658 the experiments?

659 Answer: [Yes]

660 Justification: We provide detailed information about the computational resources in Sec-
661 tion 3.4. All experiments were conducted on a distributed local setup using four NVIDIA
662 L40S GPUs, with inference powered by the VLLM engine. This setup description in-
663 cludes the hardware specifications and inference configuration necessary for reproducing
664 the experiments.

665 Guidelines:

- 666 • The answer NA means that the paper does not include experiments.
- 667 • The paper should indicate the type of compute workers CPU or GPU, internal cluster,
668 or cloud provider, including relevant memory and storage.
- 669 • The paper should provide the amount of compute required for each of the individual
670 experimental runs as well as estimate the total compute.
- 671 • The paper should disclose whether the full research project required more compute
672 than the experiments reported in the paper (e.g., preliminary or failed experiments that
673 didn't make it into the paper).

674 9. Code of ethics

675 Question: Does the research conducted in the paper conform, in every respect, with the
676 NeurIPS Code of Ethics <https://neurips.cc/public/EthicsGuidelines>?

677 Answer: [Yes]

678 Justification: The research presented in this paper fully adheres to the NeurIPS Code of
679 Ethics, ensuring ethical guidelines are followed throughout the study.

680 Guidelines:

- 681 • The answer NA means that the authors have not reviewed the NeurIPS Code of Ethics.
- 682 • If the authors answer No, they should explain the special circumstances that require a
683 deviation from the Code of Ethics.

- 684 • The authors should make sure to preserve anonymity (e.g., if there is a special consid-
685 eration due to laws or regulations in their jurisdiction).

686 **10. Broader impacts**

687 Question: Does the paper discuss both potential positive societal impacts and negative
688 societal impacts of the work performed?

689 Answer: [Yes]

690 Justification: The broader impacts of our work are discussed in Section 6.

691 Guidelines:

- 692 • The answer NA means that there is no societal impact of the work performed.
693 • If the authors answer NA or No, they should explain why their work has no societal
694 impact or why the paper does not address societal impact.
695 • Examples of negative societal impacts include potential malicious or unintended uses
696 (e.g., disinformation, generating fake profiles, surveillance), fairness considerations
697 (e.g., deployment of technologies that could make decisions that unfairly impact specific
698 groups), privacy considerations, and security considerations.
699 • The conference expects that many papers will be foundational research and not tied
700 to particular applications, let alone deployments. However, if there is a direct path to
701 any negative applications, the authors should point it out. For example, it is legitimate
702 to point out that an improvement in the quality of generative models could be used to
703 generate deepfakes for disinformation. On the other hand, it is not needed to point out
704 that a generic algorithm for optimizing neural networks could enable people to train
705 models that generate Deepfakes faster.
706 • The authors should consider possible harms that could arise when the technology is
707 being used as intended and functioning correctly, harms that could arise when the
708 technology is being used as intended but gives incorrect results, and harms following
709 from (intentional or unintentional) misuse of the technology.
710 • If there are negative societal impacts, the authors could also discuss possible mitigation
711 strategies (e.g., gated release of models, providing defenses in addition to attacks,
712 mechanisms for monitoring misuse, mechanisms to monitor how a system learns from
713 feedback over time, improving the efficiency and accessibility of ML).

714 **11. Safeguards**

715 Question: Does the paper describe safeguards that have been put in place for responsible
716 release of data or models that have a high risk for misuse (e.g., pretrained language models,
717 image generators, or scraped datasets)?

718 Answer: [Yes]

719 Justification: Upon open-sourcing our assets via Hugging Face, we will clearly specify the
720 intended use, license terms, and access restrictions (e.g., non-commercial and no-derivatives
721 use), along with detailed documentation outlining download, processing, and usage instruc-
722 tions. Furthermore, we will prominently disclose the license of the backbone model used in
723 our work, Qwen2.5-72B-Instruct, which is governed by the Qwen license agreement (see
724 huggingface.co/Qwen/Qwen2.5-72B-Instruct/LICENSE). These steps collectively support
725 transparent and ethically responsible distribution of the data and models.

726 Guidelines:

- 727 • The answer NA means that the paper poses no such risks.
728 • Released models that have a high risk for misuse or dual-use should be released with
729 necessary safeguards to allow for controlled use of the model, for example by requiring
730 that users adhere to usage guidelines or restrictions to access the model or implementing
731 safety filters.
732 • Datasets that have been scraped from the Internet could pose safety risks. The authors
733 should describe how they avoided releasing unsafe images.
734 • We recognize that providing effective safeguards is challenging, and many papers do
735 not require this, but we encourage authors to take this into account and make a best
736 faith effort.

737 **12. Licenses for existing assets**

738 Question: Are the creators or original owners of assets (e.g., code, data, models), used in
739 the paper, properly credited and are the license and terms of use explicitly mentioned and
740 properly respected?

741 Answer: [Yes]

742 Justification: All external assets used in this work, including datasets, source code, and
743 open-source models, are properly cited and employed in full accordance with their respective
744 licenses and terms of use. Publicly available sources such as PubMed Central, ClinicalTrials.gov,
745 and the NLM LitArch Open Access Subset were selected based on their open-access
746 policies, including the most restrictive Creative Commons Attribution-NonCommercial-
747 NoDerivatives (CC BY-NC-ND) license, where applicable. Pre-indexed corpora and other
748 resources from prior work (e.g., Xiong et al. (5)) are explicitly acknowledged and reused in
749 compliance with their original licensing terms. Open-source language models and software
750 frameworks, such as vLLM, are used in accordance with their licenses and properly credited.
751 Additionally, clinical case reports from the *New England Journal of Medicine* (NEJM) were
752 obtained under an exclusive license from the NEJM Group.

753 Guidelines:

- 754 • The answer NA means that the paper does not use existing assets.
- 755 • The authors should cite the original paper that produced the code package or dataset.
- 756 • The authors should state which version of the asset is used and, if possible, include a
757 URL.
- 758 • The name of the license (e.g., CC-BY 4.0) should be included for each asset.
- 759 • For scraped data from a particular source (e.g., website), the copyright and terms of
760 service of that source should be provided.
- 761 • If assets are released, the license, copyright information, and terms of use in the
762 package should be provided. For popular datasets, [paperswithcode .com/datasets](https://paperswithcode.com/datasets)
763 has curated licenses for some datasets. Their licensing guide can help determine the
764 license of a dataset.
- 765 • For existing datasets that are re-packaged, both the original license and the license of
766 the derived asset (if it has changed) should be provided.
- 767 • If this information is not available online, the authors are encouraged to reach out to
768 the asset's creators.

769 **13. New assets**

770 Question: Are new assets introduced in the paper well documented and is the documentation
771 provided alongside the assets?

772 Answer: [Yes]

773 Justification: We provide detailed documentation of the new assets introduced in this work.
774 Specifically, in Table S1 and Table S2, we summarize the six corpora used for our retrieval-
775 augmented generation (RAG) evidence corpus, including key statistics. We also list the
776 specific journals and article counts included from PubMed Central with Creative Commons
777 licenses, ensuring transparency and reproducibility of the dataset construction.

778 Guidelines:

- 779 • The answer NA means that the paper does not release new assets.
- 780 • Researchers should communicate the details of the dataset/code/model as part of their
781 submissions via structured templates. This includes details about training, license,
782 limitations, etc.
- 783 • The paper should discuss whether and how consent was obtained from people whose
784 asset is used.
- 785 • At submission time, remember to anonymize your assets (if applicable). You can either
786 create an anonymized URL or include an anonymized zip file.

787 **14. Crowdsourcing and research with human subjects**

788 Question: For crowdsourcing experiments and research with human subjects, does the paper
789 include the full text of instructions given to participants and screenshots, if applicable, as
790 well as details about compensation (if any)?

791 Answer: [NA]

792 Justification: Our paper does not involve crowdsourcing nor research with human subjects.

793 Guidelines:

- 794 • The answer NA means that the paper does not involve crowdsourcing nor research with
795 human subjects.
- 796 • Including this information in the supplemental material is fine, but if the main contribu-
797 tion of the paper involves human subjects, then as much detail as possible should be
798 included in the main paper.
- 799 • According to the NeurIPS Code of Ethics, workers involved in data collection, curation,
800 or other labor should be paid at least the minimum wage in the country of the data
801 collector.

802 15. **Institutional review board (IRB) approvals or equivalent for research with human
803 subjects**

804 Question: Does the paper describe potential risks incurred by study participants, whether
805 such risks were disclosed to the subjects, and whether Institutional Review Board (IRB)
806 approvals (or an equivalent approval/review based on the requirements of your country or
807 institution) were obtained?

808 Answer: [NA]

809 Justification: Our paper does not involve crowdsourcing nor research with human subjects.

810 Guidelines:

- 811 • The answer NA means that the paper does not involve crowdsourcing nor research with
812 human subjects.
- 813 • Depending on the country in which research is conducted, IRB approval (or equivalent)
814 may be required for any human subjects research. If you obtained IRB approval, you
815 should clearly state this in the paper.
- 816 • We recognize that the procedures for this may vary significantly between institutions
817 and locations, and we expect authors to adhere to the NeurIPS Code of Ethics and the
818 guidelines for their institution.
- 819 • For initial submissions, do not include any information that would break anonymity (if
820 applicable), such as the institution conducting the review.

821 16. **Declaration of LLM usage**

822 Question: Does the paper describe the usage of LLMs if it is an important, original, or
823 non-standard component of the core methods in this research? Note that if the LLM is used
824 only for writing, editing, or formatting purposes and does not impact the core methodology,
825 scientific rigorosity, or originality of the research, declaration is not required.

826 Answer: [Yes]

827 Justification: In this work, we adopted the open-sourced Qwen2.5-72B-Instruct model
828 as the backbone of our AI agent, which plays a central role in the core methods. The LLM
829 is integrated with specialized tools for medical reasoning and evidence retrieval, forming
830 the foundation of our multi-step diagnostic pipeline. Its usage is essential and original to the
831 system's design and performance.

832 Guidelines:

- 833 • The answer NA means that the core method development in this research does not
834 involve LLMs as any important, original, or non-standard components.
- 835 • Please refer to our LLM policy (<https://neurips.cc/Conferences/2025/LLM>)
836 for what should or should not be described.

837 **A Appendix**

838 **A.1 Database for evidence retrieval**

839 We constructed a comprehensive retrieval-augmented generation (RAG) evidence corpus by aggre-
840 gating content from six trusted medical and scientific sources to ensure clinical relevance, diversity,
841 and open accessibility. A summary of the dataset statistics, including the number of segmented
842 snippets and their average token lengths (computed using the Qwen2.5-72B-Instruct tokenizer),
843 is provided in Table S1. The corpus includes research articles published under Creative Commons
844 licenses from leading biomedical journals indexed in PubMed Central, with specific journal titles and
845 article counts detailed in Table S2 (18). We also incorporated clinical trial records from ClinicalTri-
846 als.gov, filtering for studies that had completed recruitment and were classified as Phase 3 or Phase 4,
847 or that investigated device-based or behavioral interventions (19). This selection yielded 156,887
848 trials as of March 2025. To enhance real-world clinical applicability, we included 1,479 clinical
849 case reports published by the *New England Journal of Medicine* between 2016 and March 2025.
850 We further adopted pre-indexed corpora of PubMed abstracts and Wikipedia entries from Xiong et
851 al. (5), which have demonstrated strong utility for medical question answering tasks. Finally, we
852 leveraged 8,226 open-access medical textbooks from the NLM LitArch Open Access Subset, hosted
853 by the U.S. National Library of Medicine (21). Together, these six sources form the backbone of our
854 evidence retrieval module, supporting the agent’s multi-step diagnostic reasoning with high-quality,
855 domain-relevant content.

Table S1: **Overview of data sources for evidence retrieval.** This table summarizes the six corpora comprising our RAG database. For each source, we report the number of full documents, the number of tokenized text snippets used for retrieval, and the average token length per document (as computed using the Qwen2.5-72B-Instruct tokenizer). Databases are listed in descending order of document count.

Corpus	Number of Docs	Number of Snippets	Average Length
PubMed Abstracts	23,897,881	23,897,881	290.01
Wikipedia	6,458,670	29,642,311	166.47
Clinical Trials	156,887	4,177,121	268.33
PubMed Central Articles	123,194	8,155,929	202.46
Textbooks	8,226	2,224,013	207.95
Clinical Cases	1,479	17,821	215.61

856 **A.2 Experimental benchmarks**

857 We evaluated our system using five medical question answering benchmarks: USMLE Step 1, USMLE
858 Step 2, USMLE Step 3, MedQA, and MedExpQA (Table S3). Each benchmark includes clinical case
859 descriptions, multiple-choice options, and a correct answer.

860 The USMLE is a three-step examination series designed to assess progressively advanced compe-
861 tencies required for medical practice in the United States. All steps primarily use multiple-choice
862 questions structured as clinical scenarios to evaluate critical thinking and clinical judgment. Step
863 1 focuses on foundational knowledge in the basic sciences, including physiology, pharmacology,
864 pathology, and disease mechanisms. It serves as a critical assessment of preclinical competencies
865 and includes 94 clinical cases (40). Step 2, also known as clinical knowledge, evaluates the abil-
866 ity to apply medical and clinical science in the context of supervised patient care. It emphasizes
867 diagnostic reasoning, clinical management, and ethical decision-making, with a benchmark of 109
868 questions (40). Step 3 assesses readiness for independent practice by testing advanced clinical reason-
869 ing and decision-making skills across complex scenarios, including diagnosis, prognosis, and patient
870 management. This benchmark includes 122 test cases.

871 MedQA is a curated benchmark for four-choice, free-form medical question answering, collected
872 after the USMLE board exams. It spans material from Steps 1 through 3 and covers a broad range of
873 clinical knowledge and case-based scenarios. While the original dataset includes both simplified and
874 traditional Chinese, we used the English subset, which contains 1,273 test cases (41). MedExpQA

Table S2: Journals and article counts included from PubMed Central. This table lists the 74 most represented journals in our corpus, sorted in descending order by article count. These journals span general medicine, specialty domains, and global health, contributing to a diverse and comprehensive retrieval corpus. The final row reports the total number of included articles from all journals.

Journal Title	Article Count	Journal Title	Article Count
BMJ Open	37,488	JAMA Ophthalmol	434
Proc Natl Acad Sci U S A	16,619	Lancet HIV	387
JAMA Netw Open	10,824	BMJ Health Care Inform	366
Nature	8,148	JAMA Surg	287
Cell	4,811	BMJ Neurol Open	282
Science	4,660	JAMA Dermatol	279
BMJ	3,636	Lancet Psychiatry	270
BMJ Glob Health	3,460	Lancet Public Health	264
N Engl J Med	2,159	BMJ Support Palliat Care	262
BMJ Open Qual	1,569	BMJ Nutr Prev Health	254
JAMA	1,552	Lancet Respir Med	252
BMJ Open Diabetes Res Care	1,434	JAMA Cardiol	239
Lancet	1,344	Lancet Diabetes Endocrinol	225
Neurology	1,216	Lancet Microbe	167
BMJ Open Sport Exerc Med	1,201	BMJ Ment Health	167
Lancet Reg Health West Pac	1,196	JAMA Otolaryngol Head Neck Surg	164
BMJ Case Rep	1,190	Lancet Planet Health	162
BMJ Paediatr Open	1,145	Lancet Haematol	157
Lancet Reg Health Eur	1,077	BMJ Med	154
BMJ Open Respir Res	1,031	Lancet Child Adolesc Health	154
Lancet Reg Health Am	901	BMJ Evid Based Med	136
Ann Intern Med	881	Lancet Digit Health	124
Lancet Glob Health	805	BMJ Surg Interv Health Technol	120
JAMA Intern Med	797	Lancet Gastroenterol Hepatol	117
Lancet Infect Dis	676	BMJ Oncol	114
BMJ Open Ophthalmol	656	Lancet Healthy Longev	102
JAMA Neurol	639	BMJ Sex Reprod Health	100
JAMA Health Forum	628	BMJ Mil Health	64
BMJ Open Gastroenterol	625	Lancet Rheumatol	61
Lancet Oncol	613	BMJ Open Sci	49
BMJ Qual Saf	601	BMJ Innov	46
JAMA Psychiatry	597	BMJ Simul Technol Enhanc Learn	42
JAMA Pediatr	569	JAMA Facial Plast Surg	39
BMJ Qual Improv Rep	547	Ann Intern Med Clin Cases	6
JAMA Oncol	490	BMJ Outcomes	1
Lancet Reg Health Southeast Asia	464	BMJ Clin Evid	1
BMJ Public Health	453		
Lancet Neurol	444	Total Number of Articles	123,194

Table S3: Overview of benchmark datasets used for evaluation. This table summarizes the five medical QA benchmarks evaluated in our study. For each dataset, we report the total number of test cases and the maximum number of answer choices presented per question.

Benchmark	Number of Testing Cases	Number of Choices
USMLE Step 1 (40)	94	9
USMLE Step 2 (40)	109	6
USMLE Step 3 (40)	122	6
MedQA (41)	1,273	4
MedExpQA (6)	125	5

875 follows a similar format and was constructed from the Spanish national residency medical exam. It
876 consists of 125 test cases, each with five answer choices and detailed explanations. For our evaluation,
877 we used the translated and annotated English subset (6).

878 **A.3 Backbone large language models**

879 Our AI agent was benchmarked against closed-source and open-source models, spanning general-
880 purpose and medical-specific LLMs. Specifically, we compared medical diagnosis performance with
881 leading proprietary models, including OpenAI’s GPT-4 and ChatGPT (2). On the open-source front,
882 we included recent state-of-the-art medical LLMs such as BioMistral, OpenBioLLM, UltraMedi-
883 cal, and PodGPT. For all the models evaluated in this study, including our AI agent, we reported
884 performance in the zero-shot setting.

885 We adopted the **Qwen2.5-72B-Instruct** model as the backbone of our AI agent. The open-source
886 Qwen series has demonstrated competitive performance against Meta’s LLaMA 3.1 models on various
887 open-domain benchmarks, including knowledge-based and math-based tasks (49). By default, Qwen
888 models support a context window of up to 32,768 tokens, which can be extended to 128K tokens
889 using the YaRN technique (39). However, we observed a decline in instruction-following capabilities
890 when extending the context window under vLLM version 0.6.3. Consequently, we retained the
891 default maximum context window of 32,768 tokens for all experiments. Due to computational
892 resource constraints, we focused exclusively on this model as our AI agent.

893 GPT-4 and GPT-3.5 (ChatGPT) from OpenAI are advanced general-purpose language models that
894 excel across a broad spectrum of real-world tasks. In the domain of medical question answering,
895 they have achieved state-of-the-art performance and are widely regarded as strong baselines. The
896 evaluation results for these models, specifically gpt-4-turbo and gpt-3.5-turbo, are reported
897 in (2).

898 BioMistral is the first biomedical language model based on the Mistral architecture, continually pre-
899 trained on PubMed Central articles released under Creative Commons licenses (42). It demonstrates
900 improved performance on medical benchmarks compared to baseline models. In our experiments,
901 due to its 2,048-token context window limitation, we generated up to 128 tokens. We omitted the
902 system prompt, as the Mistral chat template did not support it.

903 OpenBioLLM builds upon the LLaMA 3 architecture and is available in both 8B and 70B parameter
904 versions. These models are fine-tuned using direct preference optimization, a reinforcement learning-
905 based alignment technique (50). OpenBioLLM demonstrates competitive performance against both
906 its baseline and proprietary counterparts (43). In this study, we evaluated the 8B and 70B variants.
907 Additionally, we configured the models with a maximum context length of 8,192 tokens and generated
908 up to 1,024 tokens per response.

909 UltraMedical models, trained through supervised fine-tuning and preference-based learning, demon-
910 strate competitive performance with proprietary LLMs such as OpenAI GPT-4 (44; 50). In our
911 experiments, we evaluated both the 8B model, based on LLaMA 3.1, and the 70B model, based on
912 LLaMA 3, as the LLaMA 3.1 version of the UltraMedical 70B model was not publicly available at
913 the time of this study.

914 PodGPT is a family of language models continually pre-trained on publicly available podcasts
915 spanning the domains of science, technology, engineering, mathematics, and medicine (STEMM).
916 Designed specifically for scientific and educational applications, these models were evaluated across
917 a range of STEMM benchmarks, including datasets focused on medical question answering (22). We
918 employed the best-performing PodGPT model, based on the Llama-3.3-70B-Instruct architec-
919 ture fine-tuned with a low-rank adapter (51). To maintain consistency with the OpenBioLLM and
920 UltraMedical configurations, we set the context window to 8,192 tokens and allowed up to 1,024
921 tokens to be generated.

922 **A.4 Designed tools**

923 As illustrated in Fig. S1, we designed five specialized tools to serve as the diagnostic aid kit within
924 our AI agent. For question interpretation, the agent uses `perform_comparison` to handle multiple-
925 choice tasks and `generate_options` for open-ended scenarios, enabling flexible reasoning formats.
926 In particular, `generate_options` is tailored for scenarios lacking predefined choices, enabling the

Table S4: Parameters used in the agent’s toolset. This table outlines the parameters and their corresponding descriptions for each tool integrated into our diagnostic framework. The tools `perform_comparison`, `enable_search`, `relevance_analysis`, and `locate_evidence` are used for multiple-choice QA tasks. For open-ended QA, the `generate_options` tool is additionally employed, generating plausible answer options for further analysis.

Tool Name	Parameter	Parameter Description
<code>generate_options</code>	answers	The most likely answers based on the patient’s specific condition and needs.
<code>perform_comparison</code>	comparisons	A structured comparison of all options, detailing their relevance to the patient’s case.
<code>enable_search</code>	search	Answer ‘yes’ or ‘no’ to indicate search necessity.
<code>relevance_analysis</code>	analysis	A comprehensive analysis detailing the relevance of each document to the patient’s presentation, highlighting key matches, inconsistencies, and important findings.
<code>locate_evidence</code>	evidence	Relevant evidence applicable to the patient’s presentation, with article IDs in <quote></quote>tags.

927 agent to propose plausible answer candidates from the contextual details of the case. Additionally,
 928 the `enable_search` tool determines whether external evidence is necessary to support a diagnosis.
 929 To facilitate evidence retrieval and interpretation, `relevance_analysis` evaluates the semantic
 930 alignment between the patient’s case and retrieved documents, while `locate_evidence` identifies
 931 and grounds specific articles most pertinent to the diagnosis.

932 A.5 Evaluation models for open-ended question answering

933 In this work, we employed two state-of-the-art semantic similarity models, SFR-Embedding-2_R
 934 (SFR) and gte-Qwen2-7B-instruct (GTE), alongside BERTScore, enabling fine-grained semantic
 935 comparison between the model-generated responses and ground-truth answers (46; 36; 47). For both
 936 SFR and GTE, we used the default cosine similarity to compute phrase-level similarity, while for
 937 BERTScore, we reported the F1 metric to assess alignment at the token level.

938 The SFR-Embedding-2_R model is based on the Mistral architecture with 7 billion parameters and
 939 supports input lengths of up to 4,096 tokens (46). This model achieves strong results on the massive
 940 text embedding benchmark (MTEB), highlighting its robustness for semantic similarity tasks.

941 The gte-Qwen2-7B-instruct model was built on the Qwen2 architecture with 7 billion parameters
 942 and supports input lengths of up to 32K tokens (36). It was instruction-tuned for a range of natural
 943 language processing tasks, including retrieval, classification, and reranking. The model ranks highly
 944 on the MTEB leaderboard, demonstrating state-of-the-art performance in semantic textual similarity.

945 BERTScore evaluates the semantic similarity between two phrases by computing the cosine similarity
 946 between their contextualized token embeddings, derived from a pretrained language model (47).
 947 In our experiments, we used the `deberta-xlarge-mnli` model as the backbone for BERTScore
 948 computation. This model, with 750 million parameters, was fine-tuned on the multi-genre natural
 949 language inference tasks, making it particularly well-suited for assessing phrase and sentence-level
 950 semantic alignment in open-ended medical QA tasks.

951 A.6 Used prompts

952 To ensure fair and consistent evaluation, we employed a unified set of prompts across all open-source
 953 models in a direct-response format. Each model was paired with its designated chat template, as
 954 defined by its tokenizer specifications. For our AI agent, the primary prompt templates used for
 955 multiple-choice question answering are presented in Table S5, with a standardized SYSTEM PROMPT
 956 applied uniformly across all configurations. For the open-ended QA setting, we adapted the same
 957 templates by removing the answer choices, allowing the models to generate free-form diagnostic
 958 responses. The corresponding prompt format for open-ended questions is provided in Table S6.




Figure S1: Overview of specialized tools in the agentic framework. This figure illustrates the five custom-designed tools used by the agent for medical question answering in the open-ended setting. Each tool performs a distinct role: `generate_options` first proposes potential answers to the problem, `perform_comparison` then analyzes the candidate options in the context of the problem description, `enable_search` decides whether external evidence is needed, `relevance_analysis` assesses the contextual fit of retrieved documents, and `locate_evidence` extracts grounded evidence snippets tied to article IDs. Together, these tools enable dynamic, interpretable, and evidence-grounded reasoning.

959 A.7 Data and code availability

960 The clinical case data from NEJM used in this study are not publicly available and can be obtained
 961 under an exclusive licensing agreement with the NEJM Group. All other datasets used in this
 962 work, sourced from publicly accessible platforms such as PubMed Central, ClinicalTrials.gov, and
 963 the National Library of Medicine, will be released via Hugging Face under a Creative Commons
 964 Attribution-NonCommercial-NoDerivatives (CC BY-NC-ND) license. The full source code developed
 965 for this study, including all implementation and evaluation scripts, will be made publicly available on
 966 GitHub, along with detailed documentation and instructions to facilitate reproducibility.

Table S5: **Prompt templates for multiple-choice question answering.** This table presents the SYSTEM PROMPT and PROMPT TEMPLATE used for multiple-choice QA, along with the document formatting template and the cache-and-prune memory bank mechanism template employed by our AI agent.

SYSTEM PROMPT
You are a medical professional specializing in evidence-based medicine (EBM). Your role is to answer questions using a systematic approach, integrating the best available research evidence, clinical expertise, and patient-specific factors.
PROMPT TEMPLATE
<p>Here is the background information and question about the patient:</p> <pre><background> {background} </background></pre> <p>The available answer options are:</p> <pre><option> {option} </option></pre> <p>Follow these steps to answer the question:</p> <ol style="list-style-type: none"> 1. Compare each option with the case details, analyzing key clues in the text to identify the best choice. 2. If the question can be answered through comparison, directly return the best option term with the option capital within <code><final_result></final_result></code>tags, placing the explanation outside of the <code><final_result></code>tags. 3. If multiple options are plausible or additional evidence is needed for better decision-making, enable search to find credible sources. 4. Analyze the relevance between each document and the patient's presentation, followed by a systematic search to locate relevant evidence applicable to the patient's case. 5. While we are continuing to provide additional evidence, iterate the previous step to analyze more additional evidence. 6. Once sufficient information is gathered, return the best option term with the option capital within <code><final_result></final_result></code>tags, placing the explanation outside of the <code><final_result></code>tags.
Document template
<p>Relevant documents related to the patient's care:</p> <pre><document> {document} </document></pre>
Cache-and-prune memory bank mechanism template
<p>Here are the selected relevant documents related to the patient's care:</p> <pre><document> {document} </document></pre> <p>Review your answer and return the best option term with the option capital within the <code><final_result></final_result></code>tags, leave the explanation outside of the <code><final_result></code>tags.</p>

Table S6: **Prompt templates for open-ended question answering.** This table presents the PROMPT TEMPLATE, document formatting template, and the template for the cache-and-prune memory bank mechanism used in open-ended QA.

PROMPT TEMPLATE
<p>Here is the background information and question about the patient:</p> <pre><background> {background} </background></pre>
<p>Follow these steps to answer the question:</p> <ol style="list-style-type: none"> 1. Compare each option with the case details, analyzing key clues in the text to identify the best choice. 2. If the question can be answered through comparison, directly return the full answer term within <final_result></final_result>tags, placing the explanation outside of the <final_result>tags. 3. If multiple options are plausible or additional evidence is needed for better decision-making, enable search to find credible sources. 4. Analyze the relevance between each document and the patient's presentation, followed by a systematic search to locate relevant evidence applicable to the patient's case. 5. While we are continuing to provide additional evidence, iterate the previous step to analyze more additional evidence. 6. Once sufficient information is gathered, return the full answer term within <final_result></final_result>tags, placing the explanation outside of the <final_result>tags.
<p>Document template</p>
<p>Relevant documents related to the patient's care:</p> <pre><document> {document} </document></pre>
<p>Cache-and-prune memory bank mechanism template</p>
<p>Here are the selected relevant documents related to the patient's care:</p> <pre><document> {document} </document></pre>
<p>Review your answer and return the full answer term within the <final_result></final_result>tags, leave the explanation outside of the <final_result>tags.</p>